STERIS plc (NYSE:STE – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $239.60.
A number of research analysts have recently issued reports on the company. KeyCorp started coverage on STERIS in a research report on Tuesday, February 6th. They set an “overweight” rating and a $253.00 target price on the stock. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research report on Friday, April 12th. Stephens restated an “overweight” rating and set a $250.00 price target on shares of STERIS in a research report on Friday, February 9th. JMP Securities reiterated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a report on Thursday, February 8th. Finally, TheStreet raised STERIS from a “c+” rating to a “b” rating in a report on Wednesday, February 7th.
View Our Latest Research Report on STERIS
Institutional Trading of STERIS
STERIS Price Performance
NYSE:STE opened at $200.24 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.43 and a quick ratio of 1.49. The company has a 50 day moving average price of $225.10 and a 200-day moving average price of $217.83. STERIS has a 1-year low of $180.54 and a 1-year high of $254.00. The firm has a market cap of $19.79 billion, a price-to-earnings ratio of 35.07 and a beta of 0.79.
STERIS (NYSE:STE – Get Free Report) last released its quarterly earnings data on Wednesday, February 7th. The medical equipment provider reported $2.22 earnings per share for the quarter, beating analysts’ consensus estimates of $2.17 by $0.05. The company had revenue of $1.40 billion during the quarter, compared to analysts’ expectations of $1.35 billion. STERIS had a net margin of 10.48% and a return on equity of 13.67%. The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.02 earnings per share. Equities research analysts forecast that STERIS will post 8.67 EPS for the current year.
STERIS Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, March 22nd. Shareholders of record on Friday, February 23rd were issued a $0.52 dividend. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a $2.08 annualized dividend and a yield of 1.04%. STERIS’s payout ratio is 36.43%.
About STERIS
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Read More
- Five stocks we like better than STERIS
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- United Airlines Soars on Earnings Beat
- 5 discounted opportunities for dividend growth investors
- J.B. Hunt Hits the Skids: Lower Prices to Come
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.